Synonyms: compound 52 [PMID: 38527911] | GLPG-2737
Compound class:
Synthetic organic
Comment: GLPG2737 is a novel CFTR co-corrector (or C2 type corrector) [1]. It was designed to provide added efficacy in combination with other CFTR potentiators and correctors in triple combination cystic fibrosis therapies.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
GLPG2737 is a clinical candidate. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03128606 | A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects. | Phase 1 Interventional | Galapagos NV | ||
NCT03474042 | GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis | Phase 2 Interventional | Galapagos NV | ||
NCT03450720 | Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis | Phase 1 Interventional | Galapagos NV |